Strategic Collaboration Announced

Regeneron Pharmaceuticals Inc. has entered into a groundbreaking agreement with Fujifilm Diosynth Biotechnologies, aimed at the production and supply of Regeneron's commercial biologic medicines. This collaboration, centered at Fujifilm's campus in North Carolina, represents a total investment of over $3 billion, encompassing technology transfer and a decade-long partnership.

Commitment to Excellence

"Our partnership with Fujifilm is a testament to our shared commitment to maintaining the highest standards in biologic medicine production," stated Daniel Van Plew, Executive Vice President at Regeneron. "We are eager to leverage Fujifilm's state-of-the-art biologics manufacturing facility in Holly Springs, North Carolina, to meet growing demand."

Expanding US Production Capabilities

In addition to this partnership, Regeneron highlighted its significant investments in production and infrastructure across New York and North Carolina, with projected expenditures surpassing $7 billion. This move underscores the company's dedication to strengthening its US manufacturing footprint.